Paul J. Diaz joins Merck board effective November 2026

Merck & Co., Inc. (NYSE: MRK) announced that Paul J. Diaz, a managing partner at Cressey & Company, will join its board of directors effective Nov. 1, 2026, expanding the board to 14 members. He will stand for shareholder election in May 2027.

Diaz currently serves as managing partner at Cressey & Company, a private investment firm focused on healthcare. He previously served as president and chief executive officer of Myriad Genetics, Inc., and before that held the same role at Kindred Healthcare, a Fortune 500 healthcare services company.

Diaz also serves on the board of Centene Corporation, the Board of Trustees of Johns Hopkins Medicine, and the Board of Visitors of the Georgetown University Law Center. He holds a bachelor's degree in finance and accounting from American University and a J.D. from Georgetown University.

Rob Davis, chairman and chief executive officer of Merck, said in a statement: "We are pleased to welcome Paul Diaz to our Board. Paul brings extensive leadership and business expertise in the healthcare industry, and we look forward to his contributions and insights."

You May Also Be Interested In

• Quantum Cyber adds retired major general to its board of directors
• PlusAI files S-4 with SEC for SPAC merger targeting Nasdaq listing
• HawkEye 360 names Christina Hoggatt as SVP of global communications